Retracted: Overexpression of dopamine receptor D2 promotes colorectal cancer progression by activating the β‐catenin/ZEB1 axis

Abstract Colorectal cancer (CRC) is a recurring cancer that is often resistant to conventional therapies and therefore requires the development of molecular‐based therapeutic approaches. Dopamine receptor D2 (DRD2) is associated with the growth of many types of tumors, but its oncogenic role in CRC...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2021-09, Vol.112 (9), p.3732-3743
Main Authors: Lee, Hyunjung, Shim, Sehwan, Kong, Joon Seog, Kim, Min‐Jung, Park, Sunhoo, Lee, Seung‐Sook, Kim, Areumnuri
Format: Article
Language:English
Subjects:
Antibodies
Cancer
Catenin
Cell adhesion & migration
Cell cycle
Cell growth
Colorectal cancer
Colorectal carcinoma
Cytotoxicity
Dopamine
Dopamine D2 receptors
Gene amplification
Kinases
Lymph nodes
Medical prognosis
Metastases
Metastasis
Patients
Proteins
Stem cells
Tumorigenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Colorectal cancer (CRC) is a recurring cancer that is often resistant to conventional therapies and therefore requires the development of molecular‐based therapeutic approaches. Dopamine receptor D2 (DRD2) is associated with the growth of many types of tumors, but its oncogenic role in CRC is unclear. Here, we observed that elevated DRD2 expression was associated with a poor survival rate among patients with CRC. Depletion of DRD2 suppressed CRC cell growth and motility by downregulating β‐catenin/ZEB signaling in vitro and in vivo, whereas overexpression of DRD2 promoted CRC cell progression. Inhibition of DRD2 by the antagonist pimozide inhibited tumor growth and lymph node metastasis in vivo and enhanced the cytotoxic effects of conventional agents in vitro. Taken together, our findings indicate that targeting the DRD2/β‐catenin/ZEB1 signaling axis is a potentially promising therapeutic strategy for patients with CRC.
ISSN:1347-9032
1349-7006
DOI:10.1111/cas.15026